92 related articles for article (PubMed ID: 24213562)
1. Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells.
Grosse J; Warnke E; Wehland M; Pietsch J; Pohl F; Wise P; Magnusson NE; Eilles C; Grimm D
Apoptosis; 2014 Mar; 19(3):480-90. PubMed ID: 24213562
[TBL] [Abstract][Full Text] [Related]
2. Impact of sunitinib on human thyroid cancer cells.
Grosse J; Warnke E; Pohl F; Magnusson NE; Wehland M; Infanger M; Eilles C; Grimm D
Cell Physiol Biochem; 2013; 32(1):154-70. PubMed ID: 23867310
[TBL] [Abstract][Full Text] [Related]
3. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
D'Agostino M; Voce P; Celano M; Sponziello M; Moretti S; Maggisano V; Verrienti A; Durante C; Filetti S; Puxeddu E; Russo D
Thyroid; 2012 Feb; 22(2):138-44. PubMed ID: 22191389
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes.
Papadopoulos EI; Yousef GM; Scorilas A
Biomed Pharmacother; 2015 Mar; 70():33-40. PubMed ID: 25776476
[TBL] [Abstract][Full Text] [Related]
9. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway.
Huang KF; Zhang GD; Huang YQ; Diao Y
Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.
Abdel-Aziz AK; Shouman S; El-Demerdash E; Elgendy M; Abdel-Naim AB
Chem Biol Interact; 2014 Jun; 217():28-40. PubMed ID: 24751611
[TBL] [Abstract][Full Text] [Related]
12. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
13. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.
Festa M; Petrella A; Alfano S; Parente L
Int J Cancer; 2009 Jun; 124(11):2728-36. PubMed ID: 19230027
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
17. Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Zhang K; Wang X; Wang H
Mol Med Rep; 2014 Oct; 10(4):2065-72. PubMed ID: 25109654
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Shen WT; Wong TS; Chung WY; Wong MG; Kebebew E; Duh QY; Clark OH
Surgery; 2005 Dec; 138(6):979-84; discussion 984-5. PubMed ID: 16360381
[TBL] [Abstract][Full Text] [Related]
19. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
20. A DC-81-indole conjugate agent suppresses melanoma A375 cell migration partially via interrupting VEGF production and stromal cell-derived factor-1α-mediated signaling.
Hsieh MC; Hu WP; Yu HS; Wu WC; Chang LS; Kao YH; Wang JJ
Toxicol Appl Pharmacol; 2011 Sep; 255(2):150-9. PubMed ID: 21708181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]